Assessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation

NCT ID: NCT06682910

Last Updated: 2025-03-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-15

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Microtech-LVAD study is designed as a prospective, single arm, multi-center early feasibility study. Approximately 15 patients will be enrolled in the study. The study will be limited to patients in whom it is decided, based on routine clinical practice, that the LVAD will be implanted via a midline sternotomy. In the first 5 study patients, the device will be implanted in the RA; subsequently, the device will be implanted in the LA unless the patient is deemed at high risk of post-LVAD right heart failure, in which case the device will be placed in the RA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Microtech-LVAD study is designed as a prospective, single arm, multi-center early feasibility study. Approximately 15 patients will be enrolled in the study. The study will be limited to patients in whom it is decided, based on routine clinical practice, that the LVAD will be implanted via a midline sternotomy. In the first 5 study patients, the device will be implanted in the RA; subsequently, the device will be implanted in the LA unless the patient is deemed at high risk of post-LVAD right heart failure, in which case the device will be placed in the RA. Clinical data will be collected pre-operatively, intra-operatively, throughout the post-operative hospitalization period, at discharge and at 1, 3-6, 9 and 12 months post-index procedure

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Microtech System

Microtech System

Group Type EXPERIMENTAL

Microtech sensor pressure

Intervention Type DEVICE

Microtech sensor implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microtech sensor pressure

Microtech sensor implantation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is scheduled to undergo an elective LVAD implantation via midline sternotomy based on routine practice at the participating center.
* Patient is characterized as INTERMACS profile 2 or greater.
* Patient is able and willing to provide written informed consent.
* Patient is willing and able to comply with all required post-procedure follow-up visits.

Exclusion Criteria

* Pre-operative coagulopathy or thrombocytopenia
* For an intended LA implant, patient has a device implanted in the left atrial appendage (e.g., WATCHMAN or similar device) or a mechanical mitral valve
* Patient has an atrial myxoma
* Patient has pre-operative evidence of thrombus in the chamber in which the device is intended to be implanted
* Patient has a history of stroke or transient ischemic attack within 6 months prior to the index procedure
* History of systemic or pulmonary thromboembolism or deep vein thrombosis (DVT) within the last 6 months
* Patient has a history of congenital heart disease, including known atrial septal defect that is not corrected (including during the LVAD implantation procedure)
* Patient has severe mitral regurgitation (for an LA implant) or severe tricuspid regurgitation (for an RA implant) that is not intended to be corrected during the LVAD implantation
* Patient has known allergy to stainless steel or titanium
* Patient has noncardiac comorbidity that, in the opinion of the Principal Investigator, may limit life expectancy to less than 1 year
* Patient is pregnant or intends to become pregnant prior to completion of all protocol follow-up requirements
* Patient is participating in another investigational study that has not reached its primary endpoint
* Intraoperative identification of any anatomical finding that would preclude safe access to, or closure of, the intended atrial chamber, or fixation of the device within the chamber including, but not limited to:

1. Identification of thrombus in the atrium in which the device will be implanted
2. Atrial anatomy deemed to be too thin or fragile to accept the implant
3. Epicardial adhesions or any intraoperative finding that would complicate access or closure of the atrium in which the device is intended to be implanted
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Microtech Medical Technologies, Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH

New York, New York, United States

Site Status RECRUITING

Rabin Medical Center

Petach Tikvah, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brenda Koltun Reuven

Role: CONTACT

+972542666688

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kate Dalton

Role: primary

347 514-3366

Keren Recanati

Role: primary

+97239377838

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Microtech-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Randomized Evaluation for Failed TAVR
NCT06400342 NOT_YET_RECRUITING NA
Indicor Validation
NCT03430102 COMPLETED